Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells

Cell Cycle

Volumn 13, Issue 5, 2014, Pages 820-833

  Sokolosky, Melissa ^a   Chappell, William H ^a   Stadelman, Kristin ^a   Abrams, Stephen L ^a   Davis, Nicole M ^a   Steelman, Linda S ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

GSK 3 ; MEK; mTOR; PI3K; Rapamycin; Sorafenib; Targeted therapy; Therapy resistance; catenin

Indexed keywords

DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAPAMYCIN; TAMOXIFEN; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL TRANSFORMATION; CLONOGENESIS; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; ANTAGONISTS AND INHIBITORS; FEMALE; MCF 7 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MCF-7 CELLS; MOLECULAR TARGETED THERAPY; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; SIROLIMUS; TAMOXIFEN; TOR SERINE-THREONINE KINASES;

EID: 84897984334     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27728     Document Type: Article

References (66)

1. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107:519-27; PMID:6249596; http://dx.doi.org/10.1111/j.1432-1033.1980.tb06059.x
2. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9:2431-8; PMID:2164470
3. Fang X, Yu SX, Lu Y, Bast RC Jr., Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 2000; 97:11960-5; PMID:11035810; http://dx.doi.org/10.1073/pnas. 220413597
4. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9; PMID:8524413; http://dx.doi.org/10.1038/378785a0
5. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 1994; 303:701-4; PMID:7980435
6. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993; 296:15-9; PMID:8250835
7. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3 - an overview of an over-achieving protein kinase. Curr Drug Targets 2006; 7:1377-88; PMID:17100578; http://dx.doi.org/10.2174/1389450110607011377
8. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011; 2:538-50; PMID:21730367
9. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget 2011; 2:610-26; PMID:21881167
10. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10:3003-15; PMID:21869603; http://dx.doi.org/10.4161/cc.10.17.17119
11. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25:1064-79; PMID:21436840; http://dx.doi.org/10.1038/leu.2011.46
12. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3:192-222; PMID:21422497
13. Hart JR, Vogt PK. Phosphorylation of AKT: a mutational analysis. Oncotarget 2011; 2:467-76; PMID:21670491
14. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012; 3:954-87; PMID:23006971
15. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3:1068-111; PMID:23085539
16. Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2011; 2:1314-21; PMID:22248929
17. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci U S A 2011; 108:E1204-13; PMID:22065737; http://dx.doi.org/10.1073/pnas.1110195108
18. Shin S, Wolgamott L, Yoon SO. Glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1). Cell Cycle 2012; 11:1053-4; PMID:22391205; http://dx.doi.org/10.4161/cc.11.6.19784
19. Shin S, Wolgamott L, Tcherkezian J, Vallabhapurapu S, Yu Y, Roux PP, Yoon SO. Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 2013; •••: http://dx.doi.org/10. 1038/onc.2013.113; PMID:23584478
20. Wang H, Brown J, Gu Z, Garcia CA, Liang R, Alard P, Beurel E, Jope RS, Greenway T, Martin M. Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol 2011; 186:5217-26; PMID:21422248; http://dx.doi.org/10.4049/jimmunol.1002513
21. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2014; 28:15-33; PMID:23778311; http://dx.doi.org/10.1038/leu.2013.184
22. Fu Y, Hu D, Qiu J, Xie X, Ye F, Lu WG. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Int J Gynecol Cancer 2011; 21:439-44; PMID:21436692; http://dx.doi.org/10.1097/IGC.0b013e31820d7366
23. Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K, Naito S, Nagaoka A, Kato T, Tomita Y. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). Biochem Biophys Res Commun 2012; 423:490-5; PMID:22683636; http://dx.doi.org/10.1016/j.bbrc.2012.05.147
24. Thamilselvan V, Menon M, Thamilselvan S. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway. Int J Cancer 2011; 129:2916-27; PMID:21472727; http://dx.doi.org/10.1002/ijc.25949
25. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273:194-200; PMID:18606491; http://dx.doi.org/10.1016/j.canlet.2008.05.045
26. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005; 334:1365-73; PMID:16043125; http://dx.doi.org/10.1016/j.bbrc.2005. 07.041
27. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65:2076-81; PMID:15781615; http://dx.doi.org/10.1158/0008-5472.CAN-04-3642
28. Zhou W, Wang L, Gou SM, Wang TL, Zhang M, Liu T, Wang CY. ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Cancer Lett 2012; 316:178-86; PMID:22100174; http://dx.doi.org/10.1016/j.canlet.2011.10.033
29. Panka DJ, Cho DC, Atkins MB, Mier JW. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 2008; 283:726-32; PMID:17991738; http://dx.doi.org/10.1074/jbc.M705343200
30. Martinez-Outschoorn UE, Balliet R, Lin Z, Whitaker-Menezes D, Birbe RC, Bombonati A, Pavlides S, Lamb R, Sneddon S, Howell A, et al. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle 2012; 11:4402-13; PMID:23172369; http://dx.doi.org/10.4161/cc.22776
31. Shimizu Y, Mullins N, Blanchard Z, Elshamy WM. BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. Oncotarget 2012; 3:299-313; PMID:22431556
32. Chang S, Sharan SK. Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Oncotarget 2012; 3:5-6; PMID:22403740
33. Almeida MI, Reis RM, Calin GA. BRCA1, microRNAs and cancer predisposition: challenging the dogma. Cell Cycle 2011; 10:377; PMID:21270524; http://dx.doi.org/10.4161/cc.10.3.14738
34. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, et al. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle 2011; 10:90-9; PMID:21191178; http://dx.doi.org/10.4161/cc.10.1.14359
35. Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget 2011; 2:435-47; PMID:21646685
36. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, et al. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget 2011; 2:378-92; PMID:21623005
37. Knappskog S, Lønning PE. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget 2011; 2:251-8; PMID:21436469
38. Bazarov AV, Lee WJ, Bazarov I, Bosire M, Hines WC, Stankovich B, Chicas A, Lowe SW, Yaswen P. The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells. Cell Cycle 2012; 11:1008-13; PMID:22333593; http://dx.doi.org/10.4161/cc.11.5.19492
39. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. [Review]. Cell Cycle 2011; 10:1563-70; PMID:21502814; http://dx.doi.org/10.4161/cc.10.10.15703
40. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D, D'Orazi G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011; 10:1679-89; PMID:21508668; http://dx.doi.org/10.4161/cc.10.10.15642
41. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008; 27:4086-95; PMID:18332865; http://dx.doi.org/10.1038/onc.2008.49
42. Navolanic PM, McCubrey JA. Pharmacological breast cancer therapy (review). [review]. Int J Oncol 2005; 27:1341-4; PMID:16211230
43. Marotta LL, Polyak K. Unraveling the complexity of basal-like breast cancer. Oncotarget 2011; 2:588-9; PMID:21876228
44. Borgna S, Armellin M, di Gennaro A, Maestro R, Santarosa M. Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres. Cell Cycle 2012; 11:4242-51; PMID:23095640; http://dx.doi.org/10. 4161/cc.22543
45. Witkiewicz AK, Knudsen ES. RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapy. Cell Cycle 2011; 10:1525; PMID:21502809; http://dx.doi.org/10.4161/cc.10.10.15521
46. Lehn S, Fernö M, Jirström K, Rydén L, Landberg G. A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 2011; 10:956-62; PMID:21358261; http://dx.doi.org/10.4161/cc.10.6.15074
47. Chappell WH, Abrams SL, Montalto G, Cervello M, Martelli AM, Candido S, Libra M, Polesel J, Talamini R, Arlinghaus R, et al. Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget 2012; 3:1236-45; PMID:23100449
48. Chappell WH, Abrams SL, Franklin RA, LaHair MM, Montalto G, Cervello M, Martelli AM, Nicoletti F, Candido S, Libra M, et al. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle 2012; 11:4447-61; PMID:23159854; http://dx.doi.org/10.4161/cc.22786
49. Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Steelman LS, et al. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Adv Biol Regul 2013; 53:146-55; PMID:23073564; http://dx.doi.org/10.1016/j.jbior.2012.09.004
50. Anand A, Anand A. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients. J Natl Cancer Inst 1995; 87:1642; PMID:7563210; http://dx.doi.org/10.1093/jnci/87.21.1642
51. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R. Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 2009; 9:325; PMID:19751508; http://dx.doi.org/10.1186/1471- 2407-9-325
52. Belletti B, Baldassarre G. New light on p27(kip1) in breast cancer. Cell Cycle 2012; 11:3701-2; PMID:22895010; http://dx.doi.org/10.4161/cc.21573
53. Holz MK. The role of S6K1 in ER-positive breast cancer. Cell Cycle 2012; 11:3159-65; MID:22895181; http://dx.doi.org/10.4161/cc.21194
54. Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA, Odetallah M, Ding M, Ke Z, Luo J. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 2007; 67:7756-64; PMID:17699780; http://dx.doi.org/10.1158/0008-5472.CAN-06-4665
55. Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 2005; 65:1961-72; PMID:15753396; http://dx.doi.org/10.1158/0008-5472.CAN-04-2501
56. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, Xu A. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006; 66:11462-70; PMID:17145894; http://dx.doi.org/10.1158/0008- 5472.CAN-06-1969
57. Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 2005; 168:29-33; PMID:15631989; http://dx.doi.org/10.1083/jcb.200409067
58. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 1994; 303:701-4; PMID:7980435
59. He X, Saint-Jeannet JP, Woodgett JR, Varmus HE, Dawid IB. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 1995; 374:617-22; PMID:7715701; http://dx.doi.org/10.1038/374617a0
60. Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A 1975; 72:4435-9; PMID:172908; http://dx.doi.org/10.1073/pnas.72.11.4435
61. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-8; PMID:10440377; http://dx.doi.org/10.1038/22780
62. Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA, Odetallah M, Ding M, Ke Z, Luo J. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 2007; 67:7756-64; PMID:17699780; http://dx.doi.org/10.1158/0008-5472.CAN-06-4665
63. Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2006; 2:91-100; PMID:16556076; http://dx.doi.org/ 10.2217/14796694.2.1.91
64. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 2006; 12:5074-81; PMID:16951223; http://dx.doi.org/10.1158/ 1078-0432.CCR-06-0196
65. Meares GP, Jope RS. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J Biol Chem 2007; 282:16989-7001; PMID:17438332; http://dx.doi.org/10.1074/jbc.M700610200
66. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51:1409-16; PMID:4357757